Atossa Genetics Inc

ATOS.US
Healthcare · Biotechnology
2.42
+0.06 (+2.33%)
USD · NASDAQ

Company Information

Company Name
Atossa Genetics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US04962H5063
CIK: 0001488039
CUSIP: 04962H506
Currency: USD
Full Time Employees: 16
Phone: 206 588 0256
Fiscal Year End: December
IPO Date: Nov 08, 2012
Description:

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Address:

448 NW Market Street, Seattle, WA, United States, 98107

People

Directors & Officers

Name Title Year Born
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & President 1951
Mr. Mark J. Daniel CPA Chief Financial Officer 1977
Ms. Janet Rose Rea MSPH, RAC Senior Vice President of Research & Development NA
Ms. Delly Behen P.H.R. Senior Vice President of Business Operations NA
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
May 21, 2025 Steven C Quay N/A Purchase 749.00 $13.20 $9.89K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 6.15M Dec 31, 2025 4.11% $0.00 1.14%
Vanguard Capital Management, LLC 349.10K Mar 31, 2026 3.50% $0.00 0.00%
Ameriprise Financial Inc 255.13K Mar 31, 2026 2.56% $0.00 0.94%
BlackRock Inc 133.17K Mar 31, 2026 1.34% $0.00 0.01%
Renaissance Technologies Corp 109.01K Mar 31, 2026 1.09% $0.00 -20.73%
Geode Capital Management, LLC 97.06K Mar 31, 2026 0.97% $0.00 6.13%
UBS Group AG 92.03K Mar 31, 2026 0.92% $0.00 254.00%
Millennium Management LLC 66.74K Mar 31, 2026 0.67% $0.00 -19.45%
Vanguard Fiduciary Trust Co 52.24K Mar 31, 2026 0.52% $0.00 0.00%
State Street Corp 39.76K Mar 31, 2026 0.40% $0.00 0.00%
Northern Trust Corp 19.22K Mar 31, 2026 0.19% $0.00 -0.01%
Two Sigma Advisers, LLC 18.30K Dec 31, 2025 0.01% $0.00 0.00%
Greenberg Financial Group 18.22K Dec 31, 2025 0.01% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 16.20K Mar 31, 2026 0.16% $0.00 295.17%
Vanguard Global Advisers, LLC 3.09K Mar 31, 2026 0.03% $0.00 0.00%
JONES FINANCIAL COMPANIES LLLP 2.06K Mar 31, 2026 0.02% $0.00 4,285.11%
Tower Research Capital LLC 863.00 Mar 31, 2026 0.01% $0.00 223.22%
Royal Bank of Canada 644.00 Mar 31, 2026 0.01% $0.00 922.22%
Group One Trading, LLC 609.00 Mar 31, 2026 0.01% $0.00 0.00%
Advisor Group Holdings, Inc. 587.00 Mar 31, 2026 0.01% $0.00 -0.51%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Extended Equity Market Fund B 279.47K 0.19% ▲ 0.00% Dec 31, 2025
2 Extended Equity Market Fund E 279.47K 0.19% ▲ 0.00% Dec 31, 2025
3 Blackrock Extended Mkt Fund CF 279.47K 0.19% ▲ 0.00% Dec 31, 2025
4 Vanguard Total Stock Mkt Idx Inv 256.14K 2.57% ▲ 0.00% Jun 30, 2026
5 Columbia Small Cap Value Discv A 194.83K 1.95% ▲ 0.00% Jun 30, 2026
6 Columbia Small Cap Value Discovery Fund 194.83K 1.95% ▲ 2.96% Jun 30, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 99.07K 0.99% ▲ 0.00% Jun 30, 2026
8 U.S. Equity Market Fund B 63.32K 0.04% ▲ 0.00% Dec 31, 2025
9 U.S. Equity Market Fund 63.32K 0.04% ▲ 0.00% Dec 31, 2025
10 Blackrock US Eq Mkt Fund CF 63.32K 0.04% ▲ 0.00% Dec 31, 2025

Financial Highlights

Market Cap: $23.54M
EBITDA: $-39.58M
PEG Ratio: $0.00
Book Value: $3.54
Earnings/Share: $-4.37
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -45.54%
ROE (TTM): -78.58%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-8.83M
Trailing P/E: 0.00
Forward P/E: 7.04

Shares Statistics

Shares Outstanding: 9.97M
Shares Float: 8.58M
% Insiders: 184.70%
% Institutions: 1,633.10%
Short % Float: 7.79%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-16.00K
Gross Profit
subtotal
$-16.00K
SG&A
adjust
$-15.96M
R&D
adjust
$-21.19M
Operating Income
subtotal
$-37.14M
Other / Non-Operating Items
adjust
$2.37M
Net Income
subtotal
$-34.77M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ATOS.US!